Profile
| Metric | Value |
|---|---|
| Full Name | Incyte Corporation |
| Ticker | NASDAQ: INCY |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | |
| Website | incyte.com |
| Employees | 2,617 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $103.43 | |
| Price, 1D Change | -2.73% | |
| Market Cap | $20B | |
| - | ||
| PE Ratio | 17.35 | |
| Beta | 0.54 | |
| Revenue | $4B | |
| Revenue, 1Y Change | +14.76% | |
| EPS | $0.15 | |
| EPS, 1Y Change | -94.14% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $0.15 | |
| EPS Estimate | $6.75 | |
| EPS Est. Change | +4,255.46% | |
| Revenue | $4.24B | |
| Revenue Estimate | $4.98B | |
| Revenue Est. Change | +17.30% | |
| Current Price | $103.43 | |
| Price Target | - | $102.50 |
| Price Tgt. Change | - | -0.90% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.60 | $2.65 | -26.53% | |
| $1.29 | $0.15 | -88.01% | |
| $6.75 | N/A | +4,255.46% | |
| $7.70 | N/A | +4,868.04% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.69B | $3.70B | +0.19% | |
| $4.20B | $4.24B | +1.05% | |
| $4.98B | N/A | +17.30% | |
| $5.53B | N/A | +30.38% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +42.92% | |
| Price, 3Y | +27.96% | |
| Market Cap, 1Y | +45.05% | |
| Market Cap, 3Y | +12.78% | |
| Revenue, 1Y | +14.76% | |
| Revenue, 3Y | +42.02% | |
| EPS, 1Y | -94.14% | |
| EPS, 3Y | -96.37% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $103.43 | |
| SMA 200 | $80.72 | |
| SMA 200 vs Price | -21.96% | |
| SMA 50 | $102.08 | |
| SMA 50 vs Price | -1.31% | |
| Beta | 0.54 | |
| ATR | $3.38 | |
| 14-Day RSI | 52.77 | |
| 10-Day Volatility | 43.66% | |
| 1-Year Volatility | 34.57% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $4.24B | |
| EPS | $0.15 | |
| Gross Profit | $3.86B | |
| Gross Margin | 91.09% | |
| Operating Profit | $101.29M | |
| Operating Margin | 2.39% | |
| Net Income | $32.62M | |
| Net Margin | 0.77% | |
| EBITDA | $408.16M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 1.97 | |
| Quick Ratio | 1.94 | |
| - | ||
| F-Score | 7 | |
| Altman Z-Score | 7.03 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 17.35 | |
| PS Ratio | 4.22 | |
| PB Ratio | 4.37 | |
| EV/EBITDA | 12.92 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $3.45B | |
| Cash & Equivalents | $1.69B | |
| Total Assets | $5.48B | |
| Current Assets | $3.24B | |
| Total Liabilities | $2.03B | |
| Current Liabilities | $1.64B | |
| Total Debt | $60.34M | |
| Short Term Debt | $10.00M | |
| Accounts Payable | $197.47M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $4.14B | |
| Operating Expenses | $3.83B | |
| Cost Of Goods Sold | $377.72M | |
| SG&A | $1.22B | |
| D&A | $89.25M | |
| Interest Expense | $0.00 | |
| Income Tax | $284.02M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $335.34M | |
| CFI | $157.52M | |
| CFF | -$2.02B | |
| Capex | $100.16M | |
| Free Cash Flow | $235.17M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Morgan Stanley | → | |
| Wells Fargo | → | |
| Morgan Stanley | → | |
| Mizuho | → | |
| Barclays | → | |
| Piper Sandler | → | |
| Guggenheim | → | |
| Wells Fargo | → | |
| Truist Securities | → | |
| RBC Capital | → |
Analyst sentiment
Institutional ownership
Screeners with INCY
Data Sources & References
- INCY Official Website www.incyte.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/879169/000087916925000118/0000879169-25-000118-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/879169/000162828025004633/0001628280-25-004633-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- INCY Profile on Yahoo Finance finance.yahoo.com/quote/INCY
- INCY Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/incy
FAQ
What is the ticker symbol for Incyte Corporation?
The ticker symbol for Incyte Corporation is NASDAQ:INCY
Does Incyte Corporation pay dividends?
No, Incyte Corporation does not pay dividends
What sector is Incyte Corporation in?
Incyte Corporation is in the Healthcare sector
What industry is Incyte Corporation in?
Incyte Corporation is in the Biotechnology industry
What country is Incyte Corporation based in?
Incyte Corporation is headquartered in United States
When did Incyte Corporation go public?
Incyte Corporation initial public offering (IPO) was on November 4, 1993
Is Incyte Corporation in the S&P 500?
Yes, Incyte Corporation is included in the S&P 500 index
Is Incyte Corporation in the NASDAQ 100?
No, Incyte Corporation is not included in the NASDAQ 100 index
Is Incyte Corporation in the Dow Jones?
No, Incyte Corporation is not included in the Dow Jones index
When was Incyte Corporation last earnings report?
Incyte Corporation's most recent earnings report was on October 28, 2025
When does Incyte Corporation report earnings?
The next expected earnings date for Incyte Corporation is February 9, 2026